Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lifshitz Law PLLC Announces Investigations of Meta Platforms, Inc. (NASDAQ: META), Amplitude, Inc. (NASDAQ: AMPL), ON Semiconductor Corporation (NASDAQ: ON), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

META, ON, AMPL, AMLX

NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Lifshitz Law Firm, P.C.

Meta Platforms, Inc. (NASDAQ:META)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Apple's iOS privacy changes were having a material impact on Meta's ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (ii) Meta's mitigation efforts were either not properly implemented or ineffective; (iii) measurement of ads was not accurate as mitigation efforts were failing; and (iv) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.

If you are a META investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Amplitude, Inc. (NASDAQ:AMPL)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) Amplitude's land-and-expand strategy was years away from significantly accelerating revenues among its newer client cohorts; (ii) the rapid acceleration in the Company's 2Q21 results resulted from the ephemeral effects of the COVID-19 pandemic which had not continued by the start of the Relevant Period, as Amplitude clients were expanding at a slower pace; and (iii) as a result, Amplitude's business, operations, financial results, and prospects were materially worse than represented to investors during the Relevant Period.

If you are an AMPL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

ON Semiconductor Corporation (NASDAQ:ON)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company misrepresented: (i) the demand for the Company's silicon carbide ("SiC") and other products; and (ii) the sustainability of the Company's revenue growth, by overstating the impact of the Company's long-term supply agreements ("LTSAs") on the achievability of its revenue streams.

If you are an ON investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated RELYVRIO's commercial prospects; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, the Company had also overstated RELYVRIO's prescription rate; (v) the Company attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you are an AMLX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

ATTORNEY ADVERTISING.© 2024 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@lifshitzlaw.com

SOURCE: Lifshitz Law Firm, P.C.



View the original press release on accesswire.com